Platelet microparticles: A wide-angle perspective

Critical Reviews in Oncology/Hematology

Volumn 30, Issue 2, 1999, Pages 111-142

  Horstman, Lawrence L ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; FC RECEPTOR; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; THROMBOCYTE ACTIVATING FACTOR;

ANTICOAGULATION; BIOASSAY; CELL HETEROGENEITY; CYTOSKELETON; ENDOTHELIUM CELL; ERYTHROCYTE MEMBRANE; FLOW CYTOMETRY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LEUKOCYTE MEMBRANE; LIPID BILAYER; MEMBRANE VESICLE; QUANTITATIVE DIAGNOSIS; REVIEW; SCOTT SYNDROME; SHEAR STRESS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGLUTINATION; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; CYTOPLASMIC GRANULES; HUMANS; PLATELET ACTIVATION;

EID: 0032953002     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00044-4     Document Type: Review

References (412)

1. Chargaff E., West R. The biological significance of the thromboplastic protein of blood. J. Biol. Chem. 166:1946;189-197.
2. O'Brian J.R. The platelet-like activity of serum. Br. J. Haematol. 1:1955;223-228.
3. Wolf P. The nature and significance of platelet products in human plasma. Br. J. Haematol. 13:1967;269-288.
4. Hardisty R.M., Hutton R.A. Platelet aggregation and the availability of platelet factor 3. Br. J. Haematol. 12:1966;764-776.
5. Warren B.A., Vales O. The release of vesicles from platelets following adhesion to vessel walls in vitro. Br. J. Exp. Pathol. 53:1972;206-215.
6. Owens M.R. The role of platelet microparticles in hemostasis. Transf. Med. Rev. 8:1994;37-44.
7. Marki HH. Lipids. In: Lentner C, editor. Geigy Scientific Tables (vol. 3, Blood), Ciba-Geigy, West Caldwell, NJ, and Basle, Switzerland, 1984:115-25.
8. Butikofer P., Kuypers F.A., Xu C.M., Chiu D.T.Y., Lubin B. Enrichment of two glycosyl-phosphatidylinositol-achored proteins, acetylcholinesterase and decay accelerating factor, in vesicles released from human red blood cells. Blood. 74:1989;1481-1485.
9. 2+-dependant exocytotic elimination of C5b-9 pores. Blood. 68:1986;556-561.
10. George J.N., Pickett E.B., Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood. 68:1986;307-309.
11. Bode A.P., Orton S.M., Frye M.J., Udis B.J. Vesiculation of platelets during in vitro aging. Blood. 77:1991;887-895.
12. Lee Y.J., Horstman L.L., Janania J., Reyes Y., Kelley R., Ahn Y.S. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb. Res. 72:1993;295-304.
13. Jy W., Horstman L.L., Arce M., Ahn Y.S. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J. Lab. Clin. Med. 119:1992;334-345.
14. Horstman L.L., Jy W., Schultz D.R., Mao W.W., Ahn Y.S. Complement mediated fragmentation and lysis of opsonized platelets: gender differences in sensitivity. J. Lab. Clin. Med. 123:1994;515-525.
15. Wiedmer T., Hall S.E., Ortel T.L., Kane W.H., Rosse W.F., Sims P.J. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of PNH. Blood. 82:1993;1192-1196.
16. Horstman L.L., Jy W., Horton A., Ahn Y.S. Improved quantitation and characterization of platelet microparticles. Clin. Res. 40:1992;422A.
17. Nomura S., Yanabu M., Kido H. et al. Significance of cytokines and CD68-positive microparticles in immune thrombocytopenic purpura. Eur. J. Haematol. 55:1995;49-56.
18. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., Coller B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J. Clin. Invest. 98:1996;863-874.
19. Gris J.C., Toulon P., Brun S., Maugard C., Sarlat C., Schved J.F., Berlan J. The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Thromb. Haemost. 76:1996;38-45.
20. Abrams C.S., Ellison N., Budzynski A.Z., Shattil S.J. Direct detection of activation platelet and platelet-derived microparticles in humans. Blood. 75:1990;128-138.
21. Galli M., Grassi A., Barbui T. Platelet-derived microvesicles in thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb. Haemost. 75:1996;427-431.
22. Lee D.H., Warkentin T.E., Denomme G.A., Hayward C.P.M., Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br. J. Haemotol. 95:1996;724-731.
23. Nomura S., Komiyama Y., Matsura E. et al. Participation of aIIIbβ3 in platelet microparticle generation by collagen plus thrombin. Haemostasis. 26:1996;31-37.
24. Swords N.A., Tracy P.B., Mann K.G. Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets. Thromb. Arterioscl. 13:1993;1613-1622.
25. Kahn I., Zucker-Franklin D., Karpatkin S. Microthrombocytosis and platelet fragmentation associated with idiopathic/autoimmune thrombocytopenic purpura. Br. J. Haematol. 31:1975;449-460.
26. Solberg C., Osterud B., Little C. Platelet storage lesion: formation of platelet fragments with platelet factor 3 activity. Thromb. Res. 48:1987;559-565.
27. Miyamoto S., Marcinkiewicz C., Edmunds L.H. Jr, Niewiarowski S. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GP IIb/IIIa. Thromb. Haemost. 80:1998;225-230.
28. Hardisty H.I., Hutton R.A. The kaolin clotting time of platelet rich PRP: a test of PF3 availability. Br. J. Hematol. 11:1965;258-275.
29. Ouyang C., Ten C.-M., Huang T.-F. Characterization of snake venom components acting on blood coagulation and platelet function. Toxicon. 30:1992;945-966.
30. Hutton R.A., Warrell D.A. Action of snake venom components on the haemostatic system. Blood. Rev. 7:1993;176-189.
31. Marcus A.J., Zucker-Franklin D. Enzyme and coagulation activities of subcellular platelet fractions. J. Clin. Invest. 43:1964;1214A.
32. Spaet T.H., Cintrol J. Studies on PF3 availability. Br. J. Haematol. 11:1965;269-275.
33. Polasek J., Duckert F. Quantitative determination of platelet factor 3 activity. Thromb. Diath. Haemorh. 25:1971;532-544.
34. Sandberg H., Andersson L.-O. A highly sensitive assay of platelet factor 3 using a chromogenic substrate. Thromb. Res. 14:1979;113-124.
35. Joist J.H., Dolezel G., Lloyd J.V., Kinlough-Rathbone R.L., Mustard J.F. Platelet factor 3 availability and the platelet release reaction. J. Lab. Clin. Med. 84:1974;474-482.
36. Jy W., Horstman L.L., Wang F., Duncan R., Ahn Y.S. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb. Res. 80:1995;471-482.
37. Howard M.A., Coghlan M., David R., Pfueller S.L. Coagulation activities of plasma microparticles. Thromb. Res. 50:1988;145-156.
38. Pitney W.R., Dacie J.V. A simple method of studying the generation of thrombin in recalcified plasma. J. Clin. Pathol. 6:1953;9.
39. Owen C.A., Thompson J.H. Soybean phosphatides in prothrombin consumption and thromboplastin-generation tests: their use in recognizing 'thrombasthenic hemophilia'. Am. J. Clin. Pathol. 33:1960;197-208.
40. Bode A.P., Miller D.T. Analysis of platelet factor 3 in platelet concentrates stored for transfusion. Vox. Sang. 51:1986;299-305.
41. Opartkiattikul N., Funahara T., Hijikata-Okonomiya A., Yamaguchi N., Talad P. Development of a new method for detection of platelet factor 3 like activity. Southeast. Asian. J. Trop. Med. Public. Health. 23 (Suppl 2):1992;47-51.
42. Hijikata-Okunomiya A. A new method for the determination of prothrombine in human plasma. Thromb. Res. 57:1990;705-715.
43. Behnke O., Forer A. Blood platelet heterogeneity: evidence for two classes of platelets in man and rat. Br. J. Haematol. 84:1993;686-693.
44. Kunicki T.J., Orchekowski R., Annis D., Honda Y. Variability of integrin alpha-2-β1 activity on human platelets. Blood. 82:1993;2693-2703.
45. Johnston G.I., Pickett E.B., McEver R.P., George J.N. Heterogeneity of platelet secretion in response to thrombin demonstrated by fluorescence flow cytometry. Blood. 69:1987;1401-1403.
46. Frojmovic M., Wong T. Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometry: II. Platelet size-dependent subpopulations. Biophys. J. 59:1991;828-837.
47. Jaremo P., Sandberg-Gertzen H. Platelet density and size in inflammatory bowel disease. Thromb. Haemost. 75:1996;560-561.
48. Tao J. Effects of cyclic AMP, cyclic GMP, and protein kinase C on calcium homeostasis and mobilization in normal and thrombotic platelets. Ph.D. Thesis, Univ. of Miami, Coral Gables, FL, 1994.
49. Clemetson K.J., McGregor J.L. Characterization of platelet glycoproteins. McIntyre D.E., Gordon J.L. Characterization of platelet glycoproteins. 1987;1-32 Elsevier, Amsterdam.
50. Kunicki T.J., Newman P.J. The molecular immunology of human platelet proteins. Blood. 80:1992;1386-1404.
51. McGregor J.L. The role of human platelet membrane receptors in inflammation. Joseph M. Immunopharmacology of platelets, handbook of immunopharmacology. 1995;67 Academic Press, New York.
52. Wang J.F., Liu Z.Y., Groopman J.E. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulated migration and adhesion. Blood. 92:1998;756-764.
53. George J.N., Pickett E.B., Saucerman S., McEver R.P., Kuniki T.J., Kieffer N., Newman P.J. Platelet surface glycoproteins: studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J. Clin. Invest. 78:1986;340-348.
54. Tschoepe D., Spangenberg P., Esser J., Schwippert B., Kehrel B., Roesen P., Gries F.A. Flow-cytometric detection of surface membrane alterations and concommitant changes in the cytoskeletal actin status of activated platelets. Cytometry. 11:1990;652-656.
55. Hayward C.P.M., Smith J.W., Horsewood P., Warkentin T.E., Kelton J.G. p-155, a multimeric platelet protein that is expressed on activated platelets. J. Biol. Chem. 266:1991;7114-7120.
56. Metezalaar M.J., Heijnen H.F.G., Sixma J.J., Nieuwenhuis H.K. Identification of a 33-Kd protein associated with the a-granule membrane (GMP-33) that is expressed on the surface of activated platelets. Blood. 79:1992;372-379.
57. Hayward C.P., Rivard G.E., Kane W.H., Drouin J., Zheng S., Moore J.C., Kelton J.G. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an aggregation defect. Blood. 87:1996;4967-4978.
58. Hayward C.P.M., Cramer E.M., Song Z. et al. Studies of multimerin in human endothelial cells. Blood. 91:1998;1304-1317.
59. Fox J.E.B., Austin C.D., Boyles J.K., Steffen K. Role of the membrane skeleton in preventing the shedding of procoagulant-rich microvesicles from the platelet plasma membrane. J. Cell. Biol. 111:1990;483-493.
60. Addo J.B., Bray P.F., Grigoryev D., Faraday N., Goldschmidt-Clermont P.J. Surface recruitment but not activation of integrin aIIbβ3 (GP IIb/IIIa) requires a functional actin cytoskeleton. Arterioscl. Thromb. Vasc. Biol. 15:1995;1466-1473.
61. Holme P.A., Solum N.O., Brosstad F., Pedersen T., Kveine M. Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets. Thromb. Haemost. 79:1998;389-394.
62. Albeda S.M., Buck C.A. Integrins and other cell adhesion molecules. FASEB. J. 4:1990;2868-2880.
63. Wegner C.D. Adhesion molecules. Page C. Handbook of immunopharmacology. 1994;Academic Press, New York.
64. Shattil S.J. Function and regulation of the β3 integrins in haemostasis and vascular biology. Thromb. Haemost. 74:1995;149-155.
65. Charo I.F., Kieffer N., Phillips D.R. Platelet membrane proteins. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis. 3rd ed. 1994;189 JB Lippincott, Philadelphia, PA.
66. Hawiger J. Adhesive interactions of blood cells and the vascular wall. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis. 3rd ed. 1994;762-768 JB Lippincott, Philadelphia, PA.
67. Niewiarowski S., Holt J.C. Platelet a-granule proteins: biochemical and pathological aspects. Longnecker G.L. The platelets: physiology and pharmacology. 1985;50-84 Academic Press, New York.
68. Harrison P., Cramer E.M. Platelet alpha-granules. Blood. Rev. 7:1993;52-62.
69. Berger G., Masse J.M., Cramer E.M. Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. Blood. 87:1996;1385-1395.
70. Youssefian T., Masse J.-M., Rendu F., Guichard J., Cramer E.M. Platelet and megakaryocyte dense granules contain glycoproteins Ib and IIb-IIIa. Blood. 89:1997;4047-4057.
71. Wartiovaara U., Salven P., Mikkola H. et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb. Haemost. 80:1998;171-175.
72. Iwamoto S., Kawasaki T., Kambayashi J., Ariyoshi H., Monden M. Platelet microparticles: a carrier of platelet-activating factor? Biochem. Biophys. Res. Com. 218:1996;940-944.
73. Nomura S., Komiyama Y., Miyake T. et al. Amyloid β-protein precursor-rich platelet microparticles in thrombotic disease. Thromb. Haemost. 72:1994;519-522.
74. Schmaier A.H. Amyloid β-protein precursor: a new anticoagulant? J. Lab. Clin. Med. 130:1997;5-7.
75. Kelton J.G., Warkentin T.E., Hayward C.P.M., Murphy W.G., Moore J.C. Calpain activity in patients with thrombotic thrombocytopenic purpura is asociated with platelet microparticles. Blood. 80:1992;2246-2251.
76. Pasquet J.-M., Toti F., Nurden A.T., Dachery-Prigent J. Procoagulant activity and active calpain in platelet-derived microparticles. Thromb. Res. 82:1996;509-522.
77. Fourcade O., Simon M.-F., Viode C. et al. Secretory phosphloplipase A2 generates the novel lipid mediator lysophophatidic acid in membrane microvesicles shed from activated cells. Cell. 80:1995;919-927.
78. 2+-dependent protease during platelet activation. Blood. 69:1987;537-545.
79. Fox J.E.B. The platelet cytoskeleton. Thromb. Haemost. 70:1993;884-893.
80. Tuszynski G.P., Daniel J.L., Stewart G. Association of proteins with the platelet cytoskeleton. Semin. Hematol. 22:1985;303-312.
81. White J.G. Platelet membrane ultrastructure and its changes during platelet activation. Jamieson G.A. Platelet membrane receptors: molecular biology, immunology, biochemistry and pathology. 1988;1-32 Liss, New York.
82. Crawford N. The presence of contractile proteins in platelet microparticles isolated from human and animal platelet-free plasma. Br. J. Haematol. 21:1971;53-69.
83. Basse F., Gaffet P., Bienvenue A. Correlation between inhibition of cytoskeleton proteolysis and anti-vesiculation effect of calpeptin during A23187-induced activation of human platelets: are vesicles shed by filopod fragmentation? Biochim. Biophys. Acta. 1190:1994;217-224.
84. 2+ gradients with redistribution of glycoprotein IIb-IIIa and F-actin in activated human blood platelets. Arterioscl. Thromb. Vasc. Biol. 16:1996;230-235.
85. Yano Y., Kambayashi J., Shiba E. et al. The role of protein phosphorylation and cytoskeletal reorganization in microparticle formation from the platelet plasma membrane. Biochem. J. 299(1):1994;303-308.
86. Danielli J.F., Davson H. A contribution to the theory of thin films. J. Cell. Physiol. 5:1935;495.
87. Richards D.E., Eisner D.A. Preparation and use of resealed red cell ghosts. Ellory J.C., Young J.D. Red cell membranes: a methodological approach. 1982;165-178 Academic Press, New York.
88. Racker E., Horstman L.L. Structure and function of submitochondrial particles completely resolved with respect to coupling factor 1. J. Biol. Chem. 242:1967;2547-2551.
89. Hinckle P.C., Horstman L.L. Respiration-driven proton transport in submitochondrial particles. J. Biol. Chem. 246:1971;6024-6029.
90. Schroit A.J., Zwaal F.A. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim. Biophys. Acta. 1071:1991;313-329.
91. Zwaal R.F.A., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 89:1997;1121-1132.
92. VanDieigen G., Tans G., Rosing J., Hemker H.C. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J. Biol. Chem. 256:1981;3433-3442.
93. Rosing J., Speijer H., Zwaal R.F.A. Prothrombin activation on phospholipid membranes with positive electrostatic potential. Biochemistry. 27:1988;8-11.
94. Seigneuret M., Devaux P.F. ATP-dependent asymetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape change. Proc. Natl. Acad. Sci. USA. 81:1984;3751-3755.
95. Zhou Q., Zhou J., Stout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase: a protein mediating transbilayer movement of plasma membrane phospholipids. J. Biol. Chem. 272:1997;18240-18244.
96. Thiagarajan P., Tait J.F. Collagen induced exposure of anionic phospholipid in platelets and platelet-derived microparticles. J. Biol. Chem. 266:1991;24302-24307.
97. Zwaal R.F.A., Comfurius P., Bevers E.M. Platelet procoagulant activity and microvesicle formation: its putative role in hemostasis and thrombosis. Biochim. Biophys. Acta. 1180:1992;1-8.
98. Jy W., Horstman L.L., Homolak D., Ahn Y.S. Electrophoretic properties of platelets from normal, thrombotic and ITP patients by doppler electrophoretic light scattering analysis. Platelets. 6:1995;354-358.
99. Comfurius P., Senden J.M.G., Tilly R.H.J., Schroit A.J., Bevers E.M., Zwaal R.F.A. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim. Biophys. Acta. 1026:1990;153-160.
100. Dachary-Prigent J.D., Freyssinet J.-M., Pasquet J.-M., Carron J.-C., Nurden A.T. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometric study showing a role for free sulfhydryl groups. Blood. 81:1993;2554-2565.
101. Miyazaki Y., Nomura S., Miyake T. et al. High shear stress can initate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 88:1996;3456-3464.
102. Stewart M.W., Etches W.S., Gordon P.A. Antiphospholipid antibody-dependent C5b-9 formation. Br. J. Haematol. 96:1997;451-457.
103. 2+ responses. Blood. 90:1997;2615-2625.
104. Tans G., Rosing J., Christella M., Thomassen L.G.D., Heeb M.J., Zwaal R.F.A., Griffen J.H. Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood. 77:1991;2641-2648.
105. Bode A.P., Lust R.M. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity. Thromb. Res. 73:1994;285-300.
106. 2+]. Nature. 261:1976;58-60.
107. Lux S.E. Spectrin-actin membrane skeleton of normal and abnormal red blood cells. Semin. Hematol. 16:1979;21-51.
108. Lutz H.U., Liu S.-C., Palek J. Release of spectrin-free vesicles from human erythrocytes during ATP depeletion. I. Characterization of spectrin-free vesicles. J. Cell. Biol. 73:1977;548-560.
109. Franck P.F., Bevers E.M., Lubin B.H., Comfurius D., Chiu T.-Y., OpDenKamp J.A.F., Zwaal R.F.A. Uncoupling of the membrane skeleton from the lipid bilayer: the cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. J. Clin. Invest. 75:1985;183-190.
110. Westerman M.P., Cole E.R., Wu K. The effect of spicules obtained from sickle red cells on clotting activity. Br. J. Haematol. 56:1984;557-562.
111. Toumbis C.A., Stadler I., Ambrus J.L. Effect of red blood cells from patients with sickle cell disease on platelet factor 3 release. Am. J. Hematol. 40:1992;149-150.
112. Opartkiattikul N., Funahara T., Hijikata-Okonomiya A., Yamaguchi N., Fucharoen S., Talalak P. Detection of PF3 availability in whole blood from volunteers and β-thalassemia/HbE patients: a promising method for prediction of thrombotic tendency. Southeast. Asian. J. Trop. Med. Public. Health. 23 (Suppl 2):1992;52-59.
113. Ruf A., Pick M., Deutsch V. et al. In-vivo platelet activation correlates with red cell anionic phspholipid exposure in patients with β-thalassemia major. Br. J. Haematol. 98:1997;51-56.
114. Helley D., Eldor A., Girot R., Ducrocq R., Guillin M.C., Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and β-thalassemia. Thromb. Haemost. 76:1996;322-327.
115. Frenkel E.J., Kuypers F.A., Kamp J.A.F.O.d, Roelofsen B., Ott P. Effect of membrane cholesterol on dimyristoyl phosphadtidylcholine-induced vesiculation of human red blood cells. Biochim. Biophys. Acta. 855:1986;293-301.
116. Borovyagin V, Chernyshov V, Tarahovsky Y, Smekhova N. Dynamics of interaction of phosphatidylcholine/octadecylamine liposomes with human erythrocyte membranes: electron microscopic study. J Liposome Res 1989-1990:1;269-86.
117. Ott P., Hope M.J., Verkleij A.J., Roelofsen B., Brodbeck U., VanDeenan L.L.M. Effect of dimyristoyl phosphadtidylcholine on intact erythrocytes: release of spectrin-free vesicles without ATP depletion. Biochim. Biophys. Acta. 641:1981;179-187.
118. Yawata A., Kanzaki A., Gilsanz F., Delauney J., Yawata Y. A markedly disrupted skeletal network with abnormally distributed intramembrane particles in complete protein 4.1-deficient red blood cells (allele 4.1 Madrid): implications regarding a critical role of protein 4.1 in maintenance of the integrity of the red blood cell membrane. Blood. 90:1998;2471-2481.
119. Joseph M. Immunopharmacology of platelets. Page C. Handbook of immunopharmacology. 1995;Academic Press, New York.
120. Tracy P.B., Eide L.L., Mann K.G. Human prothrombinase complex assembly and function on isolated peripheral blood cell population. J. Biol. Chem. 260:1985;2119-21124.
121. Altieri D.C. Coagulation assembly on leukocytes in transmembrane signalling and cell adhesion. Blood. 81:1993;569-579.
122. Mackman N. Regulation of the tissue factor gene. FASEB. J. 9:1995;883-889.
123. Satta N., Toti F., Feugeas O. et al. Monocyte vesiculation as a possible mechanism of dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J. Immunol. 153:1994;3245-3255.
124. Satta N., Freyssinet J.-M., Toti F. The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide. Br. J. Hematol. 96:1997;534-542.
125. Jy W., Mao W.W., Horstman L.L., Tao J., Ahn Y.S. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood. Cells. Mol. Dis. 21:1995;217-231.
126. Barry O.P., Pratico D., FitzGerald G. Platelet microparticles enhance adhesive interactions between monocytes and endothelial cells. J. Clin. Invest. 45:1997;271A.
127. Hamilton K.K., Hattori R., Esmon C.T., Sims P.J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J. Biol. Chem. 265:1990;3809-3814.
128. Chonn A., Cullis P.R., Devine D.V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol. 146:1991;4234-4241.
129. Comis A., Easterbrook-Smith S.B. Inhibition of serum complement haemolytic activity by lipid vesicles containing phosphatidylserine. FEBS. 197:1986;321-327.
130. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo: relation to circulation lifetimes. J. Biol. Chem. 267:1992;18759-18765.
131. Xu N., Ohlin A.-K., Nilsson A. Chylomicron-induced prothrombin activation and platelet aggregation. Arterioscl. Thromb. 14:1994;1014-1020.
132. Loughrey H.C., Bally M.B., Reinish L.W., Cullis P.R. The binding of phosphatidylglycerol liposomes to rat platelets is mediated by complement. Thromb. Haemost. 64:1990;172-176.
133. Reinish L.W., Bally M.B., Loughrey H.C., Cullis P.R. Interactions of liposomes and platelets. Thromb. Haemost. 603:1988;518-523.
134. Manthei U., Nickells M.W., Barnes S.H., Ballard L.L., Cui W.Y., Atkinson J.P. Identification of a C3b/iC3 binding protein of rabbit platelets and leukocytes. J. Immunol. 140:1988;1228-1235.
135. Yokoyama I., Waxman F. Differential susceptibility of immune complexes to release from the erythrocyte CR1 receptor by factor I. Mol. Immunol. 31:1994;227-240.
136. Yokoyama I., Waxman F. Isotypic and clonal variation in the interactions between model monoclonal immune complexes and the human erythrocyte CR1 receptor. Mol. Immunol. 29:1992;935-947.
137. Zwirner J., Felber E., Burger R., Bitter-Suermann D., Riethmuller G., Feucht H.E. Classical pathway of complement activation in mammalian kidneys. Immunology. 80:1993;162-167.
138. Kroll M.H., Schafer A.I. Biochemical mechanism of platelet activation. Blood. 74:1989;1181-1195.
139. Ashby B., Daniel J.L., Smith J.B. Mechanisms of platelet activation and inhibition. Hematol. Oncol. Clin. North. Am. 4:1990;1-25.
140. Colman R.W. Receptors that activate platelets. Proc. Soc. Exp. Biol. Med. 197:1991;242-248.
141. Blockmans D., Deckmyn H., Vermylen J. Platelet activation. Blood. Rev. 9:1995;143-156.
142. Fuse I. Disorders of platelet function. Crit. Rev. Oncol. Hematol. 22:1996;1-25.
143. Haynes D.H. Effects of cyclic nucleotides and protein kinases on platelet calcium homeostasis and mobilization. Platelets. 4:1993;231-243.
144. Warren B.A., Vales O. The adhesive dendritic pseudopodium of the platelet and release reaction. Microvasc. Res. 4:1972;159-178.
145. George J.N., Thoi L.L., McManus L.M., Reimann T.A. Isolation of human platelet membrane microparticles from plasma and serum. Blood. 60:1982;834-840.
146. Polasek J. The appearance of multivesicular structures during platelet activation as observed by scanning electron microscopy. Thromb. Res. 28:1982;433-437.
147. Bode A.P., Sandberg H., Dombrose F.A., Lentz B.R. Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb. Res. 39:1984;49-61.
148. Sandberg H., Bode A.P., Dombrose F.A., Hoechli M., Lentz B.R. Expression of coagulant activity in human platelets: release of membranous vesicles providing platelet factor 1 and platelet factor 3. Thromb. Res. 39:1985;63-79.
149. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.L., Shattil S.J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J. Biol. Chem. 264:1989;17049-17057.
150. Adams G.A. Platelet aggregation. Longnecker G.L. The platelets: physiology and pharmacology. 1985;9-11 Academic Press, New York.
151. Iuliano L., Pratico D., Bonavita M.S., Violi F. Involvement of Phospholipase A2 in H2O2-dependent platelet activation. Platelets. 3:1992;87-90.
152. Mustonen P., Lassila R. Epinephrine augments platelet recruitment to immobilized collagent in flowing blood: evidence for a von Willebrand factor-mediated mechanism. Thromb. Haemost. 75:1996;175-181.
153. Polley M.J., Nachman R.L. Human platelet activation by C3a and C3a des-arg. J. Exp. Med. 158:1983;603-615.
154. Hallett M.B., Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol. Today. 16:1995;264-265.
155. Braquet P., Touqui L., Shen T.Y., Vargaftig B.B. Perspectives in platelet activating factor research. Pharm Rev. 39:1987;97-145.
156. Evangelou A.M. Platelet activating factor: implications for coronary heart and vascular diseases. Prostaglandins. Leukot. Essent. Fatty. Acids. 50:1994;1-28. (Review).
157. Lindsberg P.J., Hallenbeck J.M., Feverstein G. Platelet activating factor in stroke and brain injury. Ann Neurol. 30:1991;117-129.
158. Meade C.J., Heuer H., Kempe R. Biochemical pharmacology of platelet activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia. Biochem. Pharm. 41:1991;657-668.
159. Kurosawa M., Yamashita K.M., Kurimoto T. Increased levels of blood platelet activating factor in bronchial asthmatic patients with active symptoms. Allergy. 49:1994;60-63.
160. Siebeck M., Weipert J., Keser C., Kohl J., Spannagl M., Machleidt W., Schweiberer L. A triazolodiazepine platelet activating factor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J. Trauma. 31:1991;942.
161. Qayumi A.K., Jamieson W.R.E., Poostizadeh A. Effects of platelet activating factor antagonist CV-3988 in preservation of heart and lung for transportation. Ann. Thor. Surg. 52:1991;1026-1032.
162. Siebeck M., Kohl J., Endres S., Spannagl M., Machleidt W. Delayed treatment with platelet activating factor receptor antagonist WEB 2086 attenuates pulmonary dysfunction in porcine endotoxin shock. J. Trauma. 37:1994;745-751.
163. James-Krack M.R., Sexe R.B., Shukla S.D. Picomolar platelet activating factor mobilizes Ca to change platelet shape without activating phopholipase C or protein kinase C: simultaneous fluorometric measurements of intracellular free Ca concentration and aggregation. J. Pharm. Exp. Ther. 271:1994;824-831.
164. Yang X., Disa J., Rao A.K. Effect of 1-desamino-8-D-argenine-vasopressin (DDAVP) on human platelets. Thromb. Res. 59:1990;809-818.
165. Hirasawa A., Shibata K., Kotosai K., Tsujimoto G. Cloning functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Com. 203:1994;72-79.
166. Mannucci P.M., Cattaneo M. Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease. Haemostasis. 22:1992;276-280.
167. Scott J.P., Montgomery R.R. Therapy of von Willebrand disease. Semin. Thromb. Hemost. 19:1993;37-47.
168. Greinacher A., Potzsch B., Kiefel V., White J.G., Muller-Berghaus G., Mueller-Eckhardt C. Evidence that DDAVP transiently improves hemostasis in Bernard-Soulier syndrome independent of von Willebrand-factor. Ann. Hematol. 67:1993;149-150.
169. Ghosh S., Rao A.K. Lack of effect of 1-desamino-8-D-argenine vasopressin on direct adhesion of platelets to collagen. Thromb. Res. 70:1993;417-422.
170. Horstman L.L., Valle-Riestra B.J., Jy W., Wang F., Mao W.W., Ahn Y.S. Desmopressin [DDAVP] acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb. Res. 79:1995;163-174.
171. Mannucci P.M. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 90:1997;2515-2521.
172. McLeod B.C., Scott J.P. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII. Prog. Clin. Biol. Res. 324:1990;189-198.
173. Siljander P., Carpen O., Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood. 87:1996;4651-4663.
174. Stringer H.A.R., vanSwieten P., Heijnen H.F.G., Sixma J.J., Pannekoek H. Plasminogen activator inhibitor-1 released from activated platelet plays a key role in thrombolysis resistence. Arterioscl. Thromb. 14:1994;1452-1458.
175. Hevessy Z., Haramura G., Boda Z., Udvardy M., Muszbek L. Promotion of the crosslinking of fibrin and alpha-2-antiplasmin by platelets. Thromb. Haemost. 75:1996;161-167.
176. Konkle B.A., Schick P.K., He X.H., Laiu R.J., Mazur E.M. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. Arterioscler. Thromb. 13:1993;669-674.
177. Schafer A.I., Adelman B. Plasmin inhibition of platelet function and of arachadonic acid metabolism. J. Clin. Invest. 75:1985;456-461.
178. Schafer A.I., Mass A.K., Ware A., Johnson P.C., Rittenhouse S.E., Salzman E.W. Platelet protein phosphorylation: elevation of cytosolic calcium and inositol phospholipid breakdown in platelet activation induced by plasmin. J. Clin. Invest. 78:1986;73-79.
179. Liu L., Freedman J., Hornstein A., Dewar L., Blajchman M.A., Ofosu F.A. Plasmin accelerates platelet-dependent prothrombinase formation without activating the platelets. Br. J. Haematol. 92:1996;458-465.
180. Nakamura K., Kimuri M., Fenton J.W., Andersen T.J., Aviv A. Duality of plasmin effect on cytosolic free calcium in human platelets. Am. J. Physiol. 268:1995;C958-C967.
181. Kinlough-Rathbone R.L., Perry D.W., Rand M.L., Packham M.A. Pretreatment of human platelets with plasmin inhibits responses to thrombin but potentiates responses to low concentrations of aggregating agents including the thrombin receptor activating peptide SFLLRN. Thromb. Haemost. 77:1997;741-747.
182. Braaten J.V., Handt S., Jerome W.G., Kirkpatrick J., Lewis J.C., Hantgan R.R. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor: 1. Light scatter and ultrastructural examination of the lysis of a model platelet-fibrin thrombus. Blood. 81:1993;1290-1299.
183. Blajchman M.A., Ozge-Anwar A.H. The role of the complement system in hemostasis. Prog. Hematol. 14:1986;149-182.
184. Cugno M., Cicardi M., Bottasso B., Coppola R., Paonessa R., Mannucci P.M., Agostoni A. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood. 89:1997;3213-3218.
185. Morgan B.P., Meri S. Membrane proteins that protect against complement lysis. Spring. Semin. Immunopathol. 15:1994;369-396.
186. Pinckard R.N., Olson M.S., Kelley R.E., DeHeer D.H., Palmer J.D., O'Rourke R.A., Goldfein S. Antibody independent activation of human C1 after interaction with heart subcellular membranes. J. Immunol. 110:1973;1376-1382.
187. Pinckard R.N., Olson M.S., Giclas P.C., Terry R., Boyer J.T., O'Rourke R.A. Consumption of classical complement components by heart subcellular membranes in vitro and in patients after acute myocardial infarction. J. Clin. Invest. 56:1975;740-750.
188. Kagiyama A., Savage H.E., Michael L.H., Hanson G., Entman M.L., Rossen R.D. Molecular basis of complement activation in ischemic myocardium: identification of the specific molecules of mitochondrial origin that bind human C1q and fix complement. Circ. Res. 64:1989;607-615.
189. Peerschke E.I.B., Ghebrehiwet B. Identification and partial characterization of human platelet C1q binding sites. J. Immunol. 141:1988;3505-3511.
190. Endresen G.K.M., Mellbye O.J. Studies on the binding of complement factor C3 to the surface of human blood platelets. Haemostasis. 14:1984;269-280.
191. Houle J.J., Leddy J.P., Rosenfeld S.I. Secretion of the terminal complement proteins C5-C9 by human platelets. Clin. Immunol. Immunopathol. 50:1989;385-393.
192. Wiedmer T., Sims P.J. Effect of complement proteins C5b-9 on blood platelets. J. Biol. Chem. 260:1985;8014-8019.
193. Esser A.F. Big MAC attack: complement proteins cause leaky patches. Immun. Today. 12:1991;317-321.
194. Iida K., Whitlow M.B., Nussenzweig V. Membrane vesiculation protects erythrocytes from destruction by complement. J. Immunol. 147:1991;2638-2642.
195. Pascual M., Lutz H.U., Steiger G., Stammler P., Schifferli J.A. Release of vesicles enriched in complement receptor 1 from human erythrocytes. J. Immunol. 151:1993;397-404.
196. Wiedmer T., Esmon C.T., Sims P.J. Complement proteins C5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 68:1986;875-880.
197. Wiedmer T., Esmon C.T., Sims P.J. On the mechanism by which complement proteins C5b-9 increase platelet prothrombinase activity. J. Biol. Chem. 261:1986;14587-14592.
198. Sims P.J., Faioni E.M., Wiedmer T., Shattil S.J. Complement proteins C5b-9 cause release of membrane vesicles from from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J. Biol. Chem. 263:1988;18205-18212.
199. Wiedmer T., Shattil S., Cunningham M., Sims P.J. Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry. 29:1990;623-632.
200. Wiedmer T., Sims P.J. Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood. 78:1991;2880-2886.
201. Gilbert G.E., Sims P.J., Wiedmer T., Furie B., Furie B.C., Shattil S.J. Platelet-derived microparticles express high affinity receptors for factor VIII. J. Biol. Chem. 266:1991;17261-17268.
202. Sims P.J. Interaction of human platelets with the complement system. Kunicki T.J., George J.N. Platelet immunobiology: molecular and clinical aspects. 1989;354-386 JB Lippincott, Philadelphia, PA.
203. Sims P.J., Wiedmer T. The response of human platelets to activated components of the complement system. Immunol. Today. 12:1991;338-341.
204. Shattil S.J., Cunningham M., Wiedmer T., Zhao J., Sims P.J., Brass L.F. Regulation of glycoprotein IIb-IIIa receptor function studied with platelets permeabilized by the pore-forming complement proteins C5b-9. J. Biol. Chem. 267:1992;18424-18431.
205. Sims P.J., Rollins S.A., Wiedmer T. Regulatory control of complement on blood platelets: modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J. Biol. Chem. 264:1989;19228-19235.
206. Morgan B.P. Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. Biochem. J. 282:1992;409.
207. Horstman LL, Jy W, Morgan BP, Ahn YS. CD59 expression on platelets in ITP and PNH (XXV Congress of ISH, Cancun, Mexico). La Revista de Investigacion Clinica (Suppl) 1994:110;212 (a109).
208. Rubenstein E., Boucheix C., Worthington R.E., Carroll R.C. Anti-platelet interactions with Fcg receptor. Semin. Thromb. Hemost. 21:1995;10-22.
209. Carroll R.C., Rubinstein E., Worthington R.E., Boucheix C. Extensive C1q-mediated lysis of human platelets by IgG subclass murine monoclonal antibodies to the CD9 antigen. Thromb. Res. 59:1990;831-839.
210. DeReys S., Blom C., Lepoudre B., Declerck M., DeLey M., Vermylen J., Deckmyn H. Human platelet aggregation by murine monoclonal antibodies is subtype-dependent. Blood. 81:1993;11792-11800.
211. Brekke O.H., Michaelsen T.E., Sandlie I. The structural requirements for complement activation by IgG: does it hinge on the hinge? Immunol. Today. 16:1995;85-90. (Review).
212. Deckmyn H., DeReys S. Functional effects of human anti-platelet antibodies. Semin. Thromb. Hemost. 21:1995;46-59.
213. Nomura S., Yamaguch K., Kido H. et al. New monoclonal anti-human gamma receptor II antibodies induce platelet aggregation. Clin. Exp. Immunol. 86:1991;179-184.
214. Cines D.B., Wilson S.B., Tomaski A., Schreiber A.D. Platelet antibodies of the IgM class in immune thrombocytopenic purpura. J. Clin. Invest. 75:1985;1183-1190.
215. Nomura S., Yanabu M., Kido H. et al. Antiplatelet autoantibody-related microparticles in patients with idiopathic (autoimmune) thrombocytopenic purpura. Ann. Hematol. 62:1991;103-107.
216. Peerschke E.I.B., Ghebrehiwet B. Platelet interactions with C1q in whole blood and in the presence of immune complexes or aggregated IgG. Clin. Immunol. Immunopathol. 63:1992;45-50.
217. Johnson R.J., Pritzl P., Iida H., Alpers C.E. Platelet-complement interactions in mesangial proliferative nephritis in the rat. Am J Pathol. 138:1991;313-321.
218. Lehman H.A., Lehman L.O., Rustagi P.K., Rustagi R.N., Plunkett R.W., Farolino D.J., Conway J., Logue G.L. Complement-mediated autoimmune thrombocytopenia. New. Engl. J. Med. 316:1987;194-198.
219. Fabris F., Steffan A., Cordiano I., Borzini P., Luzzatto G., Randi M.L., Girolami A. Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia. Eur. J. Haematol. 53:1994;232-236.
220. Årfors L., Winiarski J., Lefvert A.K. Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes. Eur. J. Haematol. 56:1996;230-234.
221. Kiefel V., Salama A., Mueller-Eckhardt C. In vitro fixation of C3d and C5b-9 on platelets by human platelet reactive antibodies. Blut. 58:1989;33-37.
222. Spycher M.O., Spycher-Burger M., Spath P.J., Burckhardt J.J. Human serum induced opsonization of immunoglobulin G-coated polystyrene microspheres with complement components C3 and C4 as measured by flow cytometry. J. Immunol. Methods. 145:1991;83-92.
223. Mayes J.T., Schreiber R.D., Cooper N.R. Development and application of an enzyme-linked immunoabsorbant assay for the quantitation of alternative complement pathway activation in human serum. J. Clin. Invest. 73:1984;160-170.
224. Schreiber A.D., Cines D.B., Zmijewski C., Colman R.W. Effect of anti-P1A1 antibody on human platelets. II. Mechanism of the complement-dependent release reaction. Blood. 53:1979;578-587.
225. Winiarski J., Holm G. Platelet associated immunoglobulins and complement in idiopathic thrombocytopenic purpura. Clin. Exp. Immunol. 53:1983;201-207.
226. Hegde U.M., Bowes A., Roter B.L.T. Platelet associated complement components (PAC3c and PAC3d) in patients with autoimmune thrombocytopenia. Br. J. Haematol. 60:1985;49-55.
227. Kurata Y., Curd J.G., Tamerius J.D., McMillan R. Platelet-associated complement in chronic ITP. Br. J. Haematol. 60:1985;723-733.
228. Tsubakio T., Tani P., Curd J.G., McMillan R. Complement activation in vivo by antiplatelet antibodies in chronic immune thrombocytopenice purpura. Br. J. Haematol. 63:1986;293-300.
229. Lehman H.A., Lehman L.O., Rustagi P.K. et al. Complement mediated autoimmune thrombocytopenia. New. Engl. J. Med. 316:1987;194-198.
230. Solum N.O., Ruback-Dahlberg E., Pederson T.M., Reisberg T., Høgåsen K., Funderud S. Complement mediated permeabililization of platelets by monoclonal antibodies to CD9: inhibition by leupeptin and effects on the GP Ib-actin binding protein system. Thromb. Res. 75:1994;437-452.
231. Zucker-Franklin D., Karpatkin S. Red cell and platelet fragmentation in idiopathic thrombocytopenic purpura. New. Engl. J. Med. 297:1977;517-523.
232. Harrington W.J., Sprague C.C., Minnich V., Moore C.V., Aulvin R.C., Dubach R. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann. Int. Med. 38:1953;433-469.
233. Colman R.W., Kuckibhotla J., Schreiber A.D. Effect of heterologous antiplatelet antibody on human platelets: a new pathway to platelet alteration. Blood. 50:1977;575-585.
234. Boucheix C, Carroll RC, Worthington RE, LeCompte T, editors. Platelet response to anti-platelet antibodies. Semin Thromb Hemost 1995;21:1-116.
235. Anderson C.L., Chacko G.W., Osbourne J.M., Brandt J.T. The Fc receptor for immunoglobulin G (FcgRII) on human platelets. Semin. Thromb. Hemost. 21:1995;1-9.
236. Santos S., Zimmermann U., Neppert J., Mueller-Eckhardt C. Receptor patching and capping of platelet membranes induced by monoclonal antibodies. Blood. 67:1986;343-349.
237. White J.G. Induction of patching and its reversal on surface-activated human platelets. Br. J. Haematol. 76:1990;108-115.
238. White J.G. Functional significance of mobile receptors on human platelets. Arterioscl. Thromb. 13:1993;1236-1243.
239. Clemetson K.J. Platelet activation: signal transduction via membrane receptors. Thromb. Haemost. 74:1995;111-116.
240. Deckmyn H., Vanhoorelbeke K., Cauwenberghs N. A platelet activating antiglyoprotein Ib monoclonal antibody. Blood. 90:1997;3807-3808. (Letter with response).
241. Yanabu M., Nomura S., Fukoroi T. et al. Platelet activation induced by an antiplatelet autoantibody against CD9 antigen and its inhibition by another autoantibody in immune thrombocytopenic purpura. Br. J. Hematol. 84:1993;694-701.
242. Gruel Y.J., Nugent D.J.K., Kunicki T.J. Molecular specificity of anti-IIb/IIIa human antibodies. Semin. Thromb. Hemost. 21:1995;60-67.
243. Niessner H., Clemetson K.J., Panzer S., Mueller-Eckhardt C., Santoso S., Bettelheim P. Acquired thrombasthenia due to GPIIa/IIIba-specific platelet autoantibodies. Blood. 68:1986;571-576.
244. Yanabu M., Suzuki M., Soga T. et al. Influence of antiplatelet autoantibodies on platelet function in immune thrombocytopenic purpura. Eur. J. Haematol. 46:1991;101-106.
245. Fridman W. Fc receptors and immunoglobulin binding factors. FASEB. J. 5:1991;2684-2690.
246. Ahn Y.S., Jy W., Kolodny L., Horstman L.L., Mao W.W., Valant P.A., Duncan R.C. Activated platelet aggregates in thrombotic thrombocytopenic purpura: decrease with plasma infusions and normalization in remission. Br. J. Haematol. 95:1996;408-415.
247. Jy W., Horstman L.L., Park H., Mao W.W., Valant P., Ahn Y.S. Platelet aggregates as markers of platelet activation: characterization of flow cytometric method suitable for clinical applications. Am. J. Haematol. 57:1998;33-42.
248. Bachelot C., Rendu F., Gulino D. Anti-GPIIb/IIIa antibodies: powerful tools to investigate function and regulation of an integrin. Semin. Thromb. Hemost. 21:1995;23-36.
249. Anderson G.P., Winkel J.G.J.vd, Anderson C.L. Anti-GP IIb/IIIa (CD41) monoclonal antibody-induced platelet activaton requires Fc receptor-dependent cell-cell interaction. Br. J. Hematol. 79:1991;75-83.
250. Horsewood P., Hayward C.P.M., Warkentin T.E., Kelton J.G. Investigation of the mechanisms of monoclonal antibody-induced platelet activaton. Blood. 78:1991;1019-1026.
251. Brighton T.A., Evans S., Castaldi P.A., Chesterman C.N., Chong B.H. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood. 88:1996;194-201.
252. Karpatkin S., Xia J., Patel J., Thorbecke G.J. Serum platelet-reactive IgG of autoimmune thrombocytopenic purpura patients is not Fab'2 mediated and a function of storage. Blood. 80:1992;3164-3172.
253. Kiefel V., Spaeth P., Mueller-Eckhardt C. Immune thrombocytopenic purpura: autoimmune or immune complex disease? Br. J. Haematol. 64:1986;57.
254. Kiefel V., Santoso S., Weisheit M., Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet reactive antibodies. Blood. 70:1987;1722-1726.
255. Kokawa T., Nomura S., Yanabu M., Yasunaga K. Detection of platelet antigen for antiplatelet antibodies in idopathic thrombocytopenic purpura by flow cytometery, antigen-capture ELISA, and immunoblotting: a comparative study. Eur. J. Haematol. 50:1993;74-80.
256. McMillan R. Clinical role of antiplatelet antibody assays. Semin. Thromb. Hemost. 21:1995;37-45.
257. Baldini M., Costea N., Damashek W. The viability of stored platelets. Blood. 16:1960;1669-1692.
258. Dumaswala U.J., Dumaswala R.U., Levin D.S., Greenwalt T.J. Improved red blood cell preservation correlation with decreased loss of bands 3, 4, 1, acetylcholinesterase, and lipids in microvesicles. Blood. 87:1996;1612-1616.
259. Winokur R., Hartwig J.H. Mechanism of shape change in chilled human platelets. Blood. 85:1994;1796-1804.
260. Seghatchian M.J., Bessos H., Vickers M., Ip A., Pearce L., Grant J., Murphy W.G. Differential characteristic properties of fresh and stored platelet concentrates: influence of cold-induced shape change on microvesicle-bound and soluble glycocalicin release. Platelets. 3:1992;113. (Short Communication).
261. Bode A.P., Knupp C.L. Platelet vesiculation and loss of GP Ib during storage at 4°C. Thromb. Haemost. 65:1991;1072. (Abst 1356).
262. Bessos H., Seghatchian J., Vickers M., Ip A., Pearce L., McGill A., Murphy W.G. Differential characteristic properties of fresh and stored platelet concentrates: influence of EDTA-induced shape changes on microvesicle-bound and soluble glycocalicin release. Platelets. 3:1992;112-113. (Short Communication).
263. Correia J.J., Williams R.C. Jr Mechanisms of assembly and disassembly of microtubules. Ann. Rev. Biophys. Bioeng. 12:1983;211-235.
264. Collins C.A., Vallee R.B. Temperature-dependent reversible assembly of taxol-treated microtubules. J. Cell. Biol. 105:1987;2847-2854.
265. Sandberg H., Andersson L., Hoglund S. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from human platelets. Biochem. J. 203:1982;303-311.
266. Ratnoff O.D. Some therapeutic agents influencing hemostasis. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis. 3rd ed. 1994;1104-1133 JB Lippincott, Philadelphia, PA.
267. Rock G., Palmer D., Tittley P., McCombie N., Schoendorfer D., Drago J. Evidence of a cryogel during processing of cell-free plasma. Transfusion. 29:1989;165-169.
268. Mrowiec Z.R., Oleksowicz L., Zuckerman D., Leon-Fernandez M.D., Khorshidi M., Dutcher J.P., Puszkin E.G. Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: combined strategies for reducing platelet activation during storage. Transfusion. 36:1996;5-10.
269. Bode A.P., Miller D.T., Newman S.L., Castellani W.J., Norris H.T. Plasmin activity and complement activation during storage of citrated platelet concentrates. J. Lab. Clin. Med. 113:1989;94-102.
270. Baumgartner H.R., Muggli R., Tschopp T.B., Turitto V.T. Platelet adhesion release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb. Haemost. 35:1976;124-138.
271. Bernstein E.F., Marzec U., Clayman M.D., Swanson S., Johnston G.G. Platelet function following surface injury and shear stress: adhesion, aggregation, release, and factor 3 activity. Ann. NY. Acad. Sci. 283:1977;138-158.
272. Turitto V.T., Baumgartner H.R. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood: shear rate dependent decrease of adhesion in von Willebrands disease and the Bernard-Soulier syndrome. J. Lab. Clin. Med. 92:1978;750-764.
273. Turitto V.T., Baumgartner H.R. Platelet interaction with subendothelium in flowing rabit blood: effect of shear rate. Microvasc. Res. 17:1979;38-54.
274. Weiss H.J., Baumgartner H.R. The effect of shear rate on platelet interaction with subendothelium exposed to citrated blood. Microvasc. Res. 19:1980;352-365.
275. Willerson J.T., Yao S.K., McNatt J. et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. PNAS. Med. 88(89):1991;10624-10628.
276. Adams G.A. Platelet adhesion: past and present. Longnecker G.L. The platelets: physiology and pharmacology. 1985;18-26 Academic Press, New York.
277. Kroll M.H., Hellums J.D., McIntire L.V., Schafer A.I., Moake J.L. Platelets and shear stress. Blood. 88:1996;1525-1541.
278. Demiroglu H. The importance of erythrocyte aggregation in blood rheology: considerations on the pathophysiology of thrombotic disorders. Blood. 89:1997;4236-4242. (Letter).
279. Hakim R.M., Schafer A.I. Hemodialysis-associated platelet activation and thrombocytopenia. Am. J. Med. 78:1985;575-580.
280. Addonizio V.P. Platelet function in cardiopulmonary bypass and artificial organs. Hemat. Oncol. Clin. North. Am. 4:1990;145-155.
281. Hakim R.M., Fearon D.T., Lazarus J.M. Biocompatibility of dialysis membranes: effect of chronic complement activation. Kidney. Int. 26:1984;194-200.
282. Marcus A.J., Safier L.B., Hajjar K.A., Ullman H.L., Islam N., Broekman M.J., Eiroa A.M. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase: thromboregulation by endothelial cells. J. Clin. Invest. 88:1991;1690-1696.
283. Marcus A., Broekman M., Drosopoulos J. et al. Antithrombotic activity of of human endothelial cell ecto-ADPase/CD39. J. Invest. Med. 45:1997;214A.
284. Gemmell C.H., Ramirez S.M., Yeo E.L., Sefton M.V. Platelet activation in whole blood by artificial surface: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J. Lab. Clin. Med. 125:1995;276-287.
285. Dewanjee M.K., Kapadvanjwala M., Mao W.W. et al. A higher blood flow window of reduced thrombogenicity and acceptable fragmentation in a hollow fiber hemodialyzer. ASAIO. J. 39:1993;M363-M367.
286. Holme P.A., Orvim U., Hamers M.J.A.G., Solum N.O., Brosstad F.R., Barstad R.M., Sakariassen K.S. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenosis. Arterioscl. Thromb. Vasc. Biol. 17:1997;646-653.
287. Cattaneo M., Lombardi R., Bettega D., Lecchi A., Mannucci P.M. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arteriosl. Thromb. 13:1993;393-397.
288. Ruggeri Z.M. Commentary (on paper by Jy et al.). Blood. Cells. Mol. Dis. 21:1995;231a.
289. Lindahl U., Lidholt K., Spillman D., Kjellen L. More to 'heparin' than anticoaglation. Thromb. Res. 75:1994;1-32.
290. Sobel M., Bird K.E., Tyler-Cross R., Marques D., Toma N., Conrad H.E., Harris R.B. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation. 93:1996;992-999.
291. DeGroot P.G., Sixma J.J. Role of glycoprotein IIb/IIIa in the adhesion of platelets to collagen under flow conditions. Blood. 89:1837;1997. (Letter).
292. Girolami A., Brunette A., Fioretti D., Gravina E. Congenital thrombocytopathy (platelet factor 3 defect) with prolonged bleeding time but normal platelet adhesiveness and aggregation. Acta. Hematol. 50:1973;116-123.
293. Sultan Y., Brouet J.C., Devergie A. Isolated platelet factor 3 deficiency. New. Engl. J. Med. 294:1976;1121.
294. Minkoff I.M., Wu K.K., Walasek J., Lightfoot B., Smith-McKearn C. Bleeding disorder due to an isolated [platelet] factor 3 deficiency. Arch Int Med. 140:1980;366-367.
295. Weiss H.J. Inherited abnormalities of platelet granules and signal transduction. Colman R.W., Hirsh J., Marder V.J., Salzman E.W. Hemostasis and thrombosis. 3rd ed. 1994;679-681 JB Lippincott, Philadelphia, PA.
296. Weiss H.J., Vicic W.J., Lages B.A., Rogers J. Isolated deficiency of platelet procoagulant activity. Am. J. Med. 67:1979;206-213.
297. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.J., Shattil S.J. Assembly of the platelet prothrombinase complex is linked to viesiculation of the platelet plasma membrane: studies in Scott syndrome, an isolated defect in platelet procoagulant activity. J. Biol. Chem. 264:1989;17049-17057.
298. 2+ induced microvesiculation and deficient expression of procoagulant activity in erythrocytes from a patient with a bleeding disorder: a study in the red blood cells of Scott syndrome. Blood. 79:1992;380-388.
299. Weiss H.J. Scott syndrome: a disorder of platelet procoagulant activity. Semin. Hematol. 31:1994;312-319.
300. Toti F., Satta N., Fressinaud E., Meyer D., Freyssinet J.M. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidyl serine and hemorrhagic complications, is an inherited disorder. Blood. 87:1996;1409-1415.
301. Weiss H.J., Lages B. Family studies in Scott syndrome. Blood. 90:1997;475-476. (Letter).
302. Bevers E.M., Confurius P., Zwaal R.F. Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications. Lupus. 5:1996;480-487.
303. Dachary-Prigent J., Pasquet J.M., Fressinaud E., Toti F., Freyssinet J.M. Aminophospholipid exposure, microvesiculation and abnormal protein tyrosine phosphorylation in the platelets of a patient with Scott syndrome: a study using physiologic agonists and local anaesthetics. Br. J. Haemotolol. 99:1997;959-967.
304. Stormorken H., Holmson H., Sund R., Sakariassen K.S., Hovig T., Jellum E. Studies on the haemostatic defect in a complicated syndrome: an inverse Scott syndrome platelet membrane abnormality? Thromb. Haemost. 74:1995;1244-1251.
305. Castaman G., Yu-Feng L., Battistin E., Rodeghiero F. Characterization of a novel bleeding disorder with isolated prolonged bleeding time and deficiency of platelet microvesicle generation. Br J Haematol. 96:1997;458-463.
306. Ishii H., Salem H.H., Bell C.E., Laposata C.E., Majerus P.W. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood. 67:1986;362-365.
307. Wang L., Tran N.D., Kittaka M., Fisher M.J., Schreiber S.S., Zlokovic B.V. Thrombomodulin expression in bovine brain capillaries: anticoagulant function of the blood-brain barrier, regional differences, and regulatory mechanisms. Arterioscl. Thromb. Vasc. Biol. 17:1997;3139-3146.
308. MacDonald J.D., Remington B.J., Rodgers G.M. The skin bleeding time test as a predictor of brain bleeding time in a rat model. Thromb. Res. 76:1994;535-540.
309. Barkalow F.J., Goodman M.J., Gerritsen M.E., Mayadas T.N. Brain endothelium lack one of two pathways of P-selectin-mediated neutrophil adhesion. Blood. 88:1996;4585-4593.
310. Joseph R., D'Andrea G., Oster S.B., Welch K.M.A. Whole blood platelet function in acute ischemic stroke. Stroke. 20:1989;38-44.
311. Shah B.S., Beamer N., Coull B.M. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke. 16:1985;643-647.
312. Fujimoto T., Suzuki H., Tanoue K., Fukushima Y., Yamazaki H. Cerebrovascular injuries induced by activation of platelets in vivo. Stroke. 16:1985;245-250.
313. DiLuca M.D., Pastorino L. et al. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch Neurol. 53:1996;1162-1166.
314. Rao A.K., Goldberg R.E., Walsh P.N. Platelet coagulant activities in diabetes mellitus. J. Lab. Clin. Med. 103:1984;82-92.
315. Torr-Brown S.R., Sobel B.E. Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thromb. Res. 75:1994;473-477.
316. Ozner M.D., Ahn Y.S., Horstman L.L., Jy W., Kolodny L., Myerburg R.J. Chronic platelet activation and acute coronary syndromes in 13 middle-aged patients. Clin. Appl. Thromb. Hemost. 3:1997;46-53.
317. Tate D.A., Bode A.P., Nichols T.C., Dehmer G.J. Platelet activation detected by platelet-derived microparticles in coronary sinus blood from patients with unstable coronary syndromes. Circulation. 86 (Suppl):1992;3193A.
318. Katopodis J.N., Kolodny L., Jy W. et al. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am. J. Hematol. 54:1997;95-101.
319. Jy W., Horstman L.L., Wang F, Ahn Y.S. Procoagulant activity of platelet microparticles (PAPM) correlates with thrombotic risks. Blood. 82:1993;1111A.
320. Conley C.L., Hartman R.C. A hemorhaggic disorder caused by circulating anticoagulants in patients with disseminated lupus erythamatosus. J. Clin. Invest. 31:1952;621-622.
321. Mueh J.R., Herbst K.D., Rapaport S.I. Thrombosis in patients with the lupus anticoagulant. Ann. Int. Med. 92:1980;156-159.
322. Asherson R.A., Khamashta M.A., Baguley E., Oakley C.M., Rowell N.R., Hughes G.R.V. Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q. J. Med. 73 New. Ser. 272:1989;1103-1115.
323. Ginsberg J.S., Wells P.S., Brill-Edwards P. et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 86:1995;3685-3691.
324. Trent K., Neustater B.R., Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Am. J. Hematol. 54:1997;155-159.
325. Carron J.A., Bates R.C., Smith A.I., Tetoz T., Arellano A., Gordon D.L., Burns G.F. Factor H co-purifies with thrombospondin isolated from platelet concentrates. Biochim. Biophys. Acta. Gene. Struct. Exp. 1289:1996;305-311.
326. Gharavi S., Harris E.N., Asherson R.A., Hughes G.R.V. Anti-cardiolipin antibodies: isotype distribution and phospholipid specificity. Ann. Rheum. Dis. 46:1987;1-6.
327. Harris E.N. Antiphospholipid antibodies. Br. J. Haematol. 74:1990;1-9.
328. Roubey R.A. Autoantibodies to phospholipid binding proteins: a new view of lupus anticoagulants and other 'antiphosphoplipid' autoantibodies. Blood. 84:1994;4120-4124.
329. Triplett D.A. Protean clinical presentations of antiphospholipid antibodies (APA). Thromb. Haemost. 74:1995;329-337.
330. Chong B.H., Brighton T.C., Chesterman C.N. Antiphospholipid antibodies and platelets. Semin Thromb Hemost. 21:1995;76-84.
331. Schultz D.R. Antiphospholipid antibodies: basic immunology and assays. Semin. Arthritis. Rheum. 26:1997;724-739.
332. Exner T. Diagnostic methodologies for circulating anticoagulants. Thromb. Haemost. 74:1995;338-344.
333. Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb. Haemost. 74:1995;1185-1190.
334. Arnout J., Huybrechts E., Vanrusselt M., Vermylen J. A new lupus anticoagulant test based on platelet-derived vesicles. Br. J. Haematol. 80:1992;341-346.
335. Nomura S., Yanabu M., Miyake T. et al. Relationship of microparticles with β2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immume thrombocytopenic purpura. Ann. Hematol. 70:1995;25-30.
336. Nimpf J., Bevers E.M., Bomans P.H.H., Till U., Wurm H., Kostner G.M., Zwaal R.F. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim. Biophys. Acta. 884:1986;142-149.
337. Schousboe I. 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood. 66:1985;1086-1091.
338. Nimpf J., Wurm H., Kostner G.M. 2-glyoprotein 1 (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis. 63:1987;109-114.
339. Kaplan C., Champeix P., Blanchard D., Muller J.Y., Carton J.P. Platelet antibodies in systemic lupus erythamatosus. Br. J. Haematol. 67:1987;89-93.
340. Hou M., Stockelberg D., Kutti J., Wadenvik H. Naturally occuring IgG autoantibodies to platelet cytoskeleton tropomyosin. Thromb. Haemost. 75:1996;642-647.
341. Beer J.H., Coller B.S., Siegenthaler C. The membrane sidedness of platelet microparticles, as judged by an antibody to the C-terminus of GP IIIa, depends on the mechanism of their production. Thromb. Haemost. 65:1991;1068. (A1339).
342. Alarcon-Segovia D., Ruiz-Arguelles A., Llorente L. Broken dogma: penetration of autoantibodies into living cells. Immunol. Today. 17:1996;163.
343. Morgenstern E., Ruf A., Patscheke H. Anti-glycoprotein (GP IIb/IIIa)-gold complexes are slowly transported into alpha-granules of non activated human platelets (XIII Congress ISH, Amsterdam). Thromb. Haemost. 65:1991;1067. (a1338).
344. Nomura S., Yanabu M., Fukuroi T. et al. Anti-glycoprotein IIb/IIIa autoantibodies are reversibly internalized into platelets in idiopathic (autoimmune) thrombocytopenic purpura. Autoimmunity. 13:1992;133-140.
345. Theofilopoulos A.N. The basis of autoimmunity. Part I. Mechanisms of aberrant self-recognition. Immunol. Today. 16:1995;90-98.
346. Benoist C., Mathis D. Autoimmunity: the pathogen connection. Nature. 394:1998;227-228.
347. Arnout J. The pathogensis of the anti-phospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb. Haemost. 75:1996;536-541.
348. Lin Y.L., Wang C.-T. Activation of human platelets by the rabbit anticardiolipin antibodies. Blood. 80:1992;3135-3143.
349. Kurata Y., Hayashi S., Kosugi S., Kashiwagi H., Tomiyama Y., Kanayama Y., Matsuzawa Y. Elevated platelet-associated IgG in SLE patients due to anti-platelet autoantibody: differentiation between autoantibodies and immune complexes by ether elution. Br. J. Haematol. 85:1993;723-728.
350. Oosting J., Derkson R.H.W.M., Bobbink I.W.G., Hackeng T.M., Bouma B.N., deGroot P.G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanisms? Blood. 81:1993;2618-2625.
351. Sorice M., Arcieri P., Griggi T. et al. Inhibition of protein S b autoantibodies in patients with acquired protein S deficiency. Thromb. Haemost. 75:1996;555-559.
352. Dahlback B., Stenflow J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc. Natl. Acad. Sci. USA. 78:1981;2512.
353. Matsuda J., Saitoh N., Gohchi K., Gotoh M., Tsukamoto M. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody [see comments]. Am. J. Hematol. 47:1994;56-58.
354. Kuragaki C., Kidoguchi K., Nakamura N., Wada Y. Anti-annexin V antibodies in plasma and serum samples from patients with lupus anticoagulant [letter; comment]. Am. J. Hematol. 50:1995;68.
355. Rauch J., Janoff A.S. Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Lupus. 5:1996;498-502.
356. Nakamura N., Kuragaki C., Shidara Y., Yamaji K., Wada Y. Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties. Am. J. Hematol. 49:1995;347-348.
357. Carreras L.O., Forastiero R.R. Pathogenic role of antiprotein-phospholipid antibodies. Haemostasis. 26:1996;340-357.
358. La Rosa L., Meroni P.L., Tincani A. et al. Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome. J. Rheumatol. 21:1994;1684-1693.
359. Dubois T., Bisagni-Faure A., Coste J., Mavoungou E., Menkes C.J., Russo-Marie F., Rothhut B. High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. J. Rheumatol. 22:1995;1230-1234.
360. Rodriguez-Garcia M.I., Fernandez J.A., Rodriguez A., Fernandez M.P., Gutierrez C., Torre-Alonso J.C. Annexin V autoantibodies in rheumatoid arthritis. Ann. Rheum. Dis. 55:1996;895-900.
361. Rand J.H., Wu X.X., Andree H.A.M., Lockwood C.J., Guller S., Scher J., Harpel P.C. Pregnancy loss in the antiphospholipid antibody syndrom - a possible thrombogenic mechanism. New. Engl. J. Med. 337:1997;154-160.
362. Tokita S., Arai M., Yamamoto N. et al. Specific cross reaction of IgG anti-phosopholipid antibody with platelet glycoprotein IIIa. Thromb. Haemost. 75:1996;168-174.
363. Sorice M., Circella A., Griggi T. et al. Anticardiolipin and anti-β2-GP-I are two distinct populations of autoantibodies. Thromb. Haemost. 75:1996;303-308.
364. Galli M., Finazzi G., Bevers E.M., Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and β2-glycoprotein 1-dependent antiphospholipid antibodies. Blood. 86:1995;617-623.
365. Amiral J.F., Bridey M., Dreyfus M., Vissac A.M., Fressinaud E., Wolf M., Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin induced thrombocytopenia. Thromb. Haemost. 68:1992;95-96. (Letter).
366. Greinacher A., Potzsch B., Amiral J., Dummel V., Eichner A., Mueller-Eckhardt C. Heparin associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb. Haemost. 71:1994;247-251.
367. Visentin G.P., Ford S.E., Scott P., Aster R.H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin bound to endothelial cells. J. Clin. Invest. 93:1994;81-88.
368. Amiral J., Bridey F., Wolf M. et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73:1995;21-28.
369. Warkentin T.E., Hayward C.P., Boshkov L.K., Santos A.V., Sheppard J.A., Bode A.P., Kelton J.G. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 84:1994;3691-3699.
370. Polz E., Wurm H., Kostner G.M. Investigations on β2-glycoprotein in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int. J. Biochem. 11:1980;265-270.
371. Key N.S., Immer K., Slungaard A. Platelet factor 4 (PF4) impairs tissue factor (TF) mediated coagulation: possible role as a physiologic anticoagulant. Clin. Res. 42:1994;405a.
372. Maurer A.-M., Han Z.C., Dhermy D., Briere J. Inhibitory effect of platelet factor 4 on human erythroleukemic cells is dependent on cell surface heparan sulfate. J. Lab. Clin. Med. 127:1996;382-390.
373. Mao WW, Jy W, Kolodny L, Horstman LL, Valant P, Ahn YS. Discrimination of heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT) by flow cytometric analysis of activation marker CD62p. Thromb Haemost 1997:Suppl 448;(Abst PS-1831).
374. Boshkov L.K., Warkentin T.E., Hayward C.P.M., Andrew M., Kelton J.G. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br. J. Haematol. 84:1993;322-328.
375. Cines D.B., Tomaski A., Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. New. Engl. J. Med. 316:1987;581-589.
376. Warkentin TE, Santos AV, Hayward CPM, Boshkov LK, Kelton JG. Heparin, but not quinine-quinidine-induced, thrombocytopenia sera produce procoagulant platelet-dervived microparticles: an explanation for the differing clinical syndromes. 24th Congress ISH (London). Br J Hematol 1992:18 (Abst 69).
377. Nathanson M., Savistsky J.P. Platelet adhesive index studies in multiple sclerosis and other neurologic disorders. Bull. NY. Acad. Med. 2nd. Series. 28:1952;462-468.
378. Millar J.H.D., Merret J.D., Dalby A.M. Platelet stickiness in multiple sclerosis. J. Neurol. Neurosurg. Psychiat. 26:1966;187-189.
379. Bolton CH. Platelet behavior and plasma phospholipids in multiple sclerosis. Lancet (1/20/68) 1968:99-104.
380. Andreoli VM, Cazzullo CL. Platelet behavior in multiple sclerosis [letter on Bolton paper]. Lancet (3/9/68) 1968:528-9.
381. Andreoli V.M., Cazzullo C.L. Plasma and platelet phospholipids in multiple sclerosis patients. Life. Sci. 3(II):1969;327-334.
382. Kolodny L., Ahn Y.S., Sheremata W.A. Evidence of platelet activation in multiple sclerosis. Ann. Neurol. 40:1996;520. (Abst M117).
383. Sevush S., Jy W., Horstman L.L., Mao W.W., Kolodny L., Ahn Y.S. Platelet activation in Alzheimer's disease. Arch. Neurol. 55:1998;530-536.
384. Zubenko G.S., Teply I., Winwood E., Huff E.J., Moossy J., Sunderland T., Marinez A.J. Prospective study of increased platelet membrane fluidity as a risk factor for Alzheimer's disease: results at five years. Am. J. Psychiatry. 153:1996;420-423.
385. LeBars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia. New. Engl. J. Med. 278:1997;1327-1332.
386. Braquet P. The ginkgolides: potent platelet-activating factor antagonists isolate from Ginkgo biloba L.: chemistry, pharmacology and clinical applications. Drugs. Future. 12:1987;643-699.
387. Shaw P., Bates D., Cartlidge N.E.F., French J.M., Heaviside D., Julian D.G., Shaw D.A. Early neurological complications of coronary artery bypass surgery. Br. Med. J. 291:1985;1384-1387.
388. Smith P.L. The cerebral complications of coronary artery bypass surgery. Ann. R. Coll. Surg. Eng. 70:1988;212-216.
389. Gilman S. Neurologic complications of open heart surgery. Ann. Neurol. 28:1990;475-476.
390. Brillman J. Central nervous system complications in coronary artery bypass graft surgery. Neurol. Clin. 11:1993;475-495.
391. Harrison M.J. Neurologic complications of coronary artery bypass grafting: diffuse or focal ischemia? Ann. Thorac. Surg. 59:1995;1356-1358.
392. Zilla P., Fasol R., Groscurth P., Klepetko W., Reichenspurner H., Wolner E. Blood platelets in cardiopulmonay bypass operations. J. Thorac. Cardiovasc. Surg. 97:1989;379-388.
393. vanOeveren W., Harder M.P., Roozendaal K.J., Eijsman L., Wildevuur C.R.H. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 99:1990;788-797.
394. Wenger R.K., Lukasiewicz H., Mikuta B.S., Niewiarowski S., Edmunds L.H. Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 97:1989;235-239.
395. Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of caridopulmonary bypass surgery. Blood 1991:78 (10, Suppl 1):144a, no. 567.
396. Kestin AS, Valeri CR, Khuri SF, et al. The platelet function defect of caridopulmonary bypass surgery. Blood 1991:78 (10, Suppl 1):144a, no. 567.
397. Joseph R., Tsering C., Grunfeld S., Welch K.M.A. Platelet secretory products may contribute to neuronal injury. Stroke. 22:1991;1448-1451.
398. d'Hollosy M., Culliford A.T. Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass. Stroke. 27:1996;858-874.
399. Weiss H.J., Lages B. Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity: a comparison with Scott syndrome. Blood. 89:1997;1599-1611.
400. Grau A.J., Graf T., Hacke W. Altered influence of polymorphonuclear leukocytes on coagulation in acute ischemic stroke. Thromb. Res. 76:1994;541-549.
401. Hernandez R., Alemany M., Ordinas A., Bastida E. Influence of co-incubation and cell number of platelets and polymorphonuclear leukocytes in cellular inhibition and activation phenomena. Thromb. Res. 74:1994;255-263.
402. Lehr H.A., Olofsson A.M., Carew T.E. et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lioprotein in vivo. Lab. Invest. 71:1994;380-386.
403. Kaikita K., Ogawa O., Yasue H. et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler. Thromb. Vasc. Biol. 17:1997;2232-2237.
404. LaRosa C.A., Rohrer M.J., Benoit S.E., Rodino L.J., Barnard M.R., Michelson A.D. Human neutrophil cathepsin G is a potent platelet activator. J. Vasc. Surg. 19:1994;306-319.
405. Nomura S., Miyake T., Miyazaki Y. et al. Microparticle release from platelets by leukemic cell lines. Eur. J. Haematol. 52:1994;254-255.
406. Owens M.R., Holme S., Cardinali S. Platelet microvesicles adhere to subendothelium and promote adhesion of platelets. Thromb. Res. 66:1992;247-258.
407. Philippeaux M.M., Vesin C., Tacchini-Cottier F., Piguet P.F. Activated human platelets express β2 integrin. Eur. J. Haematol. 56:1996;130-137.
408. Hall A. Rho GTPases and the actin cytoskeleton. Science. 279:1998;509-514.
409. Miki H., Sasaki T., Takai Y., Takewana T. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. Nature. 391:1998;93-96.
410. Stenberg P.E., Barrie R.J., Pestina T.I. et al. Prolonged bleeding time with defective platelet filopodia formation in the Wistar Furth rat. Blood. 91:1998;1599-1608.
411. Schmitz G., Rothe G., Ruf A. et al. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb. Haemost. 79:1998;885-896.
412. Jy W., Horstman L.L., Park H., Mao W.W., Valant P., Ahn Y.S. Platelet aggregates as markers of platelet activation. Am. J. Hematol. 57:1998;33-42.